Russia-Approved Neuropeptide for Cognition, Stroke Recovery, and Neurological Conditions

Semax is a seven-amino-acid synthetic peptide—specifically, a fragment of human adrenocorticotropic hormone (ACTH)—developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Its chemical sequence (Met-Glu-His-Phe-Pro-Gly-Pro) corresponds to the 4–10 fragment of native ACTH, stripped of the hormonal effects that characterize the full 39-amino-acid hormone. Instead, Semax retains and amplifies ACTH’s neuroprotective and neuromodulatory properties—without triggering cortisol release or adrenocortical stimulation.

In Russia, Semax is an approved pharmaceutical agent for intranasal administration, indicated for stroke recovery, cognitive disorders, ADHD-like symptoms in children, and optic nerve atrophy. Published Russian clinical data document benefit across these indications. However, Semax remains largely absent from Western peer-reviewed literature, leaving the global neuroscience community dependent on Russian-language sources and the mechanistic plausibility of its BDNF-upregulating and melanocortin-activating pathways.

This article examines Semax with the rigor required for an evidence-based resource: we assess the science, document regulatory status, review available human data, explore mechanism, and separate claim from evidence. Our conclusion: Semax has more published human clinical data than several related peptides (e.g., Selank), and its neurobiological rationale is sound. Yet independent Western replication is essentially nonexistent. For researchers and clinicians, Semax represents a case study in how geography and language barriers can limit the global scientific conversation.

Table of Contents

Quick Facts

↑ Back to contents

What Is Semax?

↑ Back to contents

Semax is a synthetic heptapeptide—a chain of seven amino acids—whose sequence mirrors a fragment of the natural human hormone ACTH. ACTH (adrenocorticotropic hormone) is a 39-amino-acid peptide hormone secreted by the anterior pituitary gland; it stimulates the adrenal cortex to produce and release cortisol. ACTH also has neuroprotective and neuromodulatory properties, but these effects are often overshadowed by its role in the hypothalamic-pituitary-adrenal (HPA) axis and systemic cortisol regulation.

Semax represents an elegant solution: it is the 4–10 amino-acid fragment of ACTH, chemically synthesized. This fragment—Met1-Glu2-His3-Phe4-Pro5-Gly6-Pro7—retains ACTH’s ability to modulate brain function and promote neuroprotection without triggering adrenocortical hormone release. In other words, Semax activates the brain-beneficial pathways of ACTH while eliminating the systemic endocrine side effects.

Structure and Chemistry

Semax is a linear peptide with a molecular weight of approximately 823 Daltons. Its seven amino acids are ordered as follows:

1. Methionine (Met)
2. Glutamic acid (Glu)
3. Histidine (His)
4. Phenylalanine (Phe)
5. Proline (Pro)
6. Glycine (Gly)
7. Proline (Pro)

This sequence is unique among naturally occurring peptides; it does not appear as an intact fragment in other proteins or hormones, only in ACTH itself. The peptide is typically synthesized by solid-phase peptide synthesis (SPPS) and exists as a free base or as a salt (acetate or hydrochloride) depending on formulation.

Intranasal Delivery and Brain Penetration

Semax is administered intranasally—directly into the nasal cavity—rather than by injection or oral route. Intranasal peptide delivery has gained significant attention in recent years because the nasal epithelium offers a unique anatomical shortcut to the central nervous system (CNS). The olfactory and trigeminal nerve pathways in the nasal mucosa provide routes that bypass the blood-brain barrier (BBB), allowing peptides that would normally be excluded or rapidly degraded in the bloodstream to reach the brain.

Semax’s intranasal formulations in Russia are supplied as sterile solutions: 0.1% solution (1 mg/mL) and 1% solution (10 mg/mL). Standard dosing involves instillation into the nostril, typically 1–3 drops or a spray per nostril, 1–3 times daily. The half-life in plasma is very short—on the order of minutes—but the intranasal route achieves CNS penetration; whether Semax reaches all brain regions uniformly remains unclear from published data.

Origins and Discovery

↑ Back to contents

Semax was synthesized and characterized at the Institute of Molecular Genetics (IMG) of the Russian Academy of Sciences, under the direction of Vladimir Seredenin and colleagues, during the 1980s and 1990s. The original concept arose from observations that ACTH and related peptides possessed neuroprotective effects independent of their endocrine functions. Russian researchers hypothesized that by isolating and synthesizing the 4–10 fragment, they could create a compound that retained ACTH’s brain benefits while eliminating hormonal side effects.

Early preclinical studies in rodents and other animal models demonstrated that Semax could enhance learning and memory, promote neuronal survival following ischemic injury, and modulate neuroinflammatory and oxidative stress markers. These findings catalyzed further development, leading to clinical trials in Russia beginning in the 1990s and early 2000s. By the early 2000s, Semax had received regulatory approval in Russia for intranasal use in stroke recovery, cognitive disorders, and optic nerve disease.

In Western scientific literature, Semax remained largely unknown until the 2010s, when researchers interested in nootropics and peptide therapeutics began to encounter Russian-language publications and sought to understand the compound’s mechanisms. Today, the vast majority of Semax literature is published in Russian or Russian-language journals, with only a handful of English-language peer-reviewed publications by non-Russian authors. This geographic and linguistic divide has resulted in Semax being relatively obscure in North America and Europe, despite its established clinical use and regulatory approval in Russia.

Mechanism of Action

↑ Back to contents

Semax’s neuroprotective and neuromodulatory effects are mediated through several interconnected pathways. Unlike full-length ACTH, which activates the melanocortin-2 (MC2) receptor on adrenocortical cells, the 4–10 fragment (Semax) preferentially activates melanocortin-3 and melanocortin-4 (MC3 and MC4) receptors—both of which are abundantly expressed in the brain. This distinction is critical: it explains why Semax does not stimulate the HPA axis or cortisol release.

BDNF and TrkB Signaling

One of the most robust findings in the Semax literature is the upregulation of brain-derived neurotrophic factor (BDNF) and activation of its high-affinity receptor, tropomyosin receptor kinase B (TrkB). BDNF is a key neurotrophin—a signaling molecule that promotes neuronal survival, growth, plasticity, and synaptic strength. Activation of TrkB triggers downstream signaling cascades (PI3K/Akt, MAPK/ERK) that enhance neuroprotection and facilitate long-term potentiation (LTP), a cellular mechanism underlying learning and memory.

Russian studies report that intranasal or intravenous Semax increases BDNF levels in cerebrospinal fluid (CSF) and brain tissue in animal models. This finding is mechanistically attractive: BDNF elevation is associated with cognitive enhancement, neuroprotection after ischemia, and antidepressant effects—all consistent with Semax’s reported clinical benefits.

Melanocortin System and Neuropeptide Modulation

The melanocortin system extends beyond the adrenal gland. MC3 and MC4 receptors are expressed throughout the hypothalamus, brainstem, and limbic structures. Activation of these receptors modulates the release and turnover of neurotransmitters—particularly dopamine and serotonin—and influences neural circuits governing mood, motivation, arousal, and executive function. Russian studies suggest Semax may increase dopaminergic tone in prefrontal cortex and striatum, potentially explaining reported improvements in attention and cognitive processing speed.

Antioxidant and Anti-inflammatory Actions

Semax appears to modulate oxidative stress and neuroinflammatory responses, partly through activation of BDNF/TrkB signaling and partly through direct suppression of pro-inflammatory cytokine (IL-6, TNF-α) production in glial cells. In ischemic stroke models, Semax has been shown to reduce infarct volume, inhibit neuronal apoptosis, and preserve BBB integrity—effects consistent with both antioxidant and anti-inflammatory mechanisms.

Neuropeptide Receptor Cross-Talk

Emerging evidence suggests Semax may also interact with other neuropeptide systems—including opioid receptors, neurotensin receptors, and others—to modulate pain perception, stress resilience, and mood. The full extent of these interactions remains incompletely characterized.

Summary: Semax’s primary mechanistic pathways involve MC3/MC4 receptor activation (leading to BDNF/TrkB upregulation and neurotransmitter modulation) and modulation of oxidative stress and neuroinflammation. These mechanisms are plausible, supported by preclinical data, and align with known neurobiology. However, most mechanism-of-action research is from Russian laboratories, and independent confirmation in Western research settings is limited.

Key Research Areas

↑ Back to contents

Published studies on Semax have explored its effects across several clinical and research domains. The most robust data come from stroke recovery and cognitive disorders; other indications are supported by smaller or preliminary studies.

Stroke and Ischemic Brain Injury

Russian clinical trials and observational studies have examined Semax in acute ischemic stroke and the post-stroke recovery phase. The rationale is strong: Semax’s BDNF-upregulating and neuroprotective properties align with the biological challenge of post-stroke rehabilitation—halting apoptosis, promoting neural plasticity, and facilitating recovery of motor and cognitive function. Several Russian studies report faster functional recovery, improved neurological scores (NIHSS, modified Rankin scale), and better outcomes at 6 and 12 months in Semax-treated stroke patients compared to controls. However, these studies are typically small (n = 50–150), published in Russian, and lack the rigor of large multicenter randomized controlled trials (RCTs) standard in Western neurology.

Cognitive Disorders and Vascular Dementia

Semax has been studied in patients with mild-to-moderate cognitive impairment, vascular cognitive impairment, and age-related cognitive decline. Reported outcomes include improvements in memory, executive function, and attention as measured by neuropsychological batteries. Again, studies are predominantly Russian, small-to-moderate in size, and lack Western replication.

ADHD-Like Symptoms in Children

Russian pediatric neurology has explored Semax for attention and hyperactivity disorders. Several studies report improvements in attention, impulse control, and behavioral symptoms. The evidence is preliminary and the generalizability to non-Russian populations is uncertain.

Optic Nerve Atrophy

Semax is approved in Russia for optic nerve atrophy—a condition of progressive degeneration of the optic nerve leading to visual loss. Studies, again from Russian centers, report stabilization or modest improvement in visual acuity and visual fields. The mechanism is presumed to involve BDNF-mediated neuroprotection of retinal ganglion cells.

Mood and Depression

A few studies have examined Semax in mood disorders, particularly depression. The rationale involves dopamine and serotonin modulation via melanocortin pathways. Results are mixed and preliminary.

Preclinical Models: Ischemia, Aging, Cognitive Impairment

Extensive preclinical work in animal models (rats, mice, gerbils) has shown Semax efficacy in reducing ischemic infarct volume, improving spatial learning and memory (Morris water maze, radial arm maze), reducing oxidative stress markers, and promoting neuroprotection in various injury models. These studies provide mechanistic support for clinical use but do not directly translate to human efficacy.

Common Claims versus Current Evidence

↑ Back to contents

Human Evidence Landscape

↑ Back to contents

The human evidence base for Semax is modest in size and predominantly Russian. A comprehensive literature review would reveal approximately 15–25 peer-reviewed human studies, the vast majority published in Russian neurology, psychiatry, and gerontology journals or conference proceedings. English-language publications are rare.

Stroke Recovery: Representative Studies

Guekht et al. (2000s–2010s) conducted several prospective studies of Semax in acute ischemic stroke. Typical designs involved randomization to Semax intranasal (usually 5–10 mcg/kg/day or fixed-dose 200–400 mcg daily) versus control for 10–14 days, followed by assessment of neurological recovery at 2 weeks, 3 months, and 6 months post-stroke. Outcomes included NIHSS score, modified Rankin scale, and neuropsychological testing. Reported results showed faster improvement in NIHSS scores and better functional outcomes in Semax-treated groups; however, these studies were single-center, had modest sample sizes (typically 60–100 subjects), and lacked detailed reporting of methods, randomization procedures, and blinding status—limitations that reduce confidence in the findings by Western standards.

Cognitive Disorders: Russian Clinical Experience

Several Russian observational and comparative studies examined Semax in patients with cognitive impairment (vascular cognitive impairment, age-related decline, post-stroke cognitive deficits). Typical study designs involved 4–12 weeks of Semax intranasal, with cognitive testing before and after. Reported improvements in memory, attention, and processing speed are consistent but not overwhelming in magnitude. Comparison to published outcomes with other cognitive enhancers (e.g., piracetam, donepezil) is difficult because studies employ different patient populations and outcome measures.

Pediatric ADHD: Limited Data

A handful of Russian studies have examined Semax in children with ADHD-like symptoms or attention problems. Sample sizes are small (n = 20–50), and outcomes are measured by behavioral rating scales and performance tests. Results suggest modest improvements but lack the methodological rigor of modern pediatric ADHD trials.

Optic Nerve Atrophy: Ophthalmology Data

Russian ophthalmology centers have published small studies of Semax in optic nerve atrophy. Outcomes include visual acuity, visual field, and OCT imaging. Reported results suggest stabilization or modest improvement, but studies are small, lack control groups, and have not been replicated in Western settings.

Western Replication: Essentially Absent

To date, there are no large, rigorous, Western-led RCTs of Semax in any indication. No studies have been published by major neurology or cognitive neuroscience groups in North America or Western Europe. This absence is striking and reflects Semax’s obscurity in the West, regulatory barriers to peptide drugs, and the geographic concentration of Semax development and clinical use in Russia.

Safety, Risks, and Limitations

↑ Back to contents

Reported Adverse Events in Published Trials

Intranasal Semax is reported as well-tolerated in published Russian clinical trials. Adverse events are rare and typically mild: occasional reports of nasal irritation, mild headache, sleep disturbances (usually transient), and rarely, mild dizziness or anxiety. No serious adverse events (hospitalization, organ toxicity, severe hypersensitivity) have been reported in the available literature. Long-term safety studies (beyond 6–12 months) are absent, so the safety profile over years of use is unknown.

HPA Axis and Cortisol: The Key Safety Advantage

A major theoretical safety advantage of Semax over full-length ACTH is the absence of HPA axis activation. ACTH potently stimulates cortisol release; chronic ACTH exposure or exogenous ACTH administration can lead to Cushing’s syndrome, immunosuppression, and metabolic derangements. Semax, by contrast, does not activate the MC2 receptor on adrenal cells and does not stimulate cortisol secretion. Published studies measuring cortisol (both baseline and after stimulation testing) show no significant changes with Semax therapy. This is a genuine safety advantage, though long-term studies are sparse.

Immunogenicity and Tolerance

Peptide drugs carry a theoretical risk of immunogenicity—i.e., the immune system may recognize the peptide as foreign and mount an antibody response, leading to neutralization and loss of efficacy or immune-mediated adverse events. For Semax, immunogenicity is rarely discussed in published literature. The peptide is short (7 amino acids) and incorporates common amino acids found in human proteins, which may reduce immunogenicity risk. However, long-term, repeated dosing could theoretically induce antibody formation. Whether this occurs clinically and whether it affects Semax efficacy is undocumented.

Intranasal Route Considerations

Intranasal peptide delivery, while avoiding first-pass metabolism and offering brain access, carries specific risks. Potential issues include:

• Nasal epithelial irritation: Repeated intranasal dosing can cause mucosal irritation, rhinitis, or (rarely) damage to nasal epithelium. Semax is reported as minimally irritating, but long-term nasal effects are not well-characterized.
• Variability in brain penetration: The degree of CNS penetration via intranasal route depends on dose, formulation, individual nasal anatomy, and mucosal permeability—all sources of variability and unpredictability.
• Bacterial contamination: Improperly preserved or handled intranasal solutions can harbor bacteria; fortunately, Russian pharmaceutical Semax products are manufactured to pharmaceutical standards.

Drug Interactions: Largely Unknown

Semax’s interactions with other medications have not been systematically studied. Theoretically, agents that modulate monoamine systems (SSRIs, dopaminergic drugs) might interact with Semax’s neurotransmitter-modulating effects. Conversely, the risk may be modest, given Semax’s short plasma half-life and presumed limited systemic exposure. Caution is warranted in patients taking multiple CNS-active drugs, but specific interaction data are absent.

Populations at Higher Risk

Semax has not been formally studied in pregnant or nursing women, young children (though some pediatric ADHD studies exist), or individuals with severe hepatic or renal disease. Caution is warranted in these populations. Additionally, individuals with a history of pituitary or hypothalamic disease should use Semax cautiously, though the lack of HPA axis activation is reassuring.

Genetic and Biochemical Variability

Melanocortin receptors (MC3, MC4) are subject to genetic variation. Polymorphisms in MC3R and MC4R genes could theoretically affect individual responses to Semax, though this has not been explored. Similarly, BDNF polymorphisms (e.g., the BDNF Val66Met variant) might influence responsiveness; this is speculative and untested.

Long-Term Efficacy: Tolerance and Tachyphylaxis

Whether Semax’s efficacy is maintained with long-term daily dosing is unclear. Peptide receptors can undergo desensitization or downregulation with chronic exposure, potentially leading to diminished response over weeks or months. Russian clinical practice anecdotally suggests that intermittent dosing (e.g., “courses” of 10–14 days followed by breaks) may maintain responsiveness, but this has not been systematically validated.

Summary of Safety: Semax appears well-tolerated at therapeutic doses in the short-to-medium term, with a genuine safety advantage over full-length ACTH due to lack of HPA axis activation. However, long-term safety data are limited, drug interaction studies are absent, and immunogenicity, tolerance, and nasal epithelial effects with chronic use remain undocumented. Prudence and informed consent are essential for any individual considering Semax, particularly for long-term use.

Legal and Regulatory Status

↑ Back to contents

Russia

In Russia, Semax is a registered pharmaceutical agent approved by the Russian Ministry of Health. Approved indications include acute ischemic stroke, post-stroke cognitive and motor recovery, mild-to-moderate cognitive disorders, ADHD-like symptoms in children, and optic nerve atrophy. Formulations are manufactured by Russian pharmaceutical companies (e.g., Peptides LLC, based in St. Petersburg) and are available through Russian pharmacies and hospitals. The regulatory pathway was faster than typical Western drug approvals, reflecting both the scientific environment of post-Soviet Russia and regulatory frameworks more permissive of peptide drugs than Western authorities.

United States (FDA)

Semax is not approved by the U.S. FDA and is not under active investigation in FDA-regulated clinical trials. The compound cannot be legally sold or marketed as a pharmaceutical or dietary supplement in the United States. However, importation for personal use or research may occupy a gray area; the FDA’s enforcement approach to imported peptides used privately is inconsistent. Individuals seeking Semax in the U.S. face legal and supply-chain risks.

European Union

Semax is not approved by the European Medicines Agency (EMA) and is not marketed in European Union member states as a pharmaceutical. Like the U.S., EU regulatory frameworks are skeptical of unapproved peptides.

WADA (World Anti-Doping Agency)

Semax is not listed on the WADA Prohibited List. This means it is not classified as a performance-enhancing substance in sports. However, WADA closely monitors the neuropeptide landscape, and future versions of the Prohibited List could change this status. Athletes should verify current WADA guidance before use.

Clinical Trial Status

ClinicalTrials.gov (the U.S. National Institutes of Health clinical trial registry) shows no active or completed trials of Semax in the United States or Western countries. Russian clinical trial registries may contain Semax trials, but these are not typically registered in international databases and are therefore less visible to Western researchers.

Legal Status for Individuals and Researchers

In most Western countries, possession of Semax is neither explicitly legal nor explicitly illegal. The regulatory gray area persists because Semax is not approved as a pharmaceutical but is also not a scheduled controlled substance. Individuals importing Semax from Russia or purchasing it online assume regulatory and supply-chain risks: the authenticity of products, contamination, and potential legal consequences (depending on jurisdiction) are all unknowns. Researchers interested in Semax face barriers to conducting trials in Western institutions, as most IRBs (Institutional Review Boards) and ethics committees would require an IND (Investigational New Drug) application or equivalent, which is unlikely to be granted for an unapproved compound without substantial pilot data.

Research Protocols

↑ Back to contents

For researchers seeking to conduct Semax investigations, a brief overview of typical protocol considerations:

Study Design

Most published Semax studies have employed one of the following designs:

• Randomized, double-blind, placebo-controlled trial (RCT): The gold standard. Participants randomized to Semax or placebo; assessors blind to assignment. Duration typically 2–12 weeks, with follow-up at 3–6 months.
• Open-label prospective study: Participants and assessors aware of treatment assignment. Useful for preliminary efficacy and safety signal detection.
• Retrospective observational study: Examination of medical records; limited for causal inference but can generate hypotheses.

Primary Outcomes

Choice of outcome measures depends on the indication:

• Stroke: NIHSS (National Institutes of Health Stroke Scale), modified Rankin scale, Barthel Index (functional independence), cognitive screening (MMSE, MoCA).
• Cognitive impairment: Validated neuropsychological batteries (e.g., Cambridge Cognitive Examination, Consortium to Establish a Registry for Alzheimer’s Disease—CERAD); processing speed, memory, executive function.
• Mood: Hamilton Depression Rating Scale (HDRS), Patient Health Questionnaire-9 (PHQ-9), visual analogue scales for mood.
• ADHD-like symptoms: Continuous Performance Test (CPT), SNAP-IV rating scale, behavioral assessments.

Mechanistic Biomarkers

To elucidate mechanism, studies should include:

• BDNF quantification (serum or CSF).
• Inflammatory cytokines (IL-6, TNF-α, CRP).
• Oxidative stress markers (8-OHdG, lipid peroxides).
• Cortisol (to verify lack of HPA axis activation).
• Neuroimaging (structural or functional MRI to assess brain volume, connectivity changes).

Sample Size and Statistical Analysis

Most published Semax studies have been underpowered by modern standards (n = 30–100). Future studies should employ a priori power calculations (typically 80–90% power, α = 0.05) and pre-specify primary and secondary outcomes. Analysis should account for baseline imbalances and employ intention-to-treat approaches.

Regulatory and Ethical Considerations

In Western settings, researchers would need to:

• Obtain Institutional Review Board (IRB) or ethics committee approval.
• Submit an IND application (in the U.S.) or equivalent regulatory filing, detailing chemistry, manufacturing, nonclinical pharmacology/toxicology, and prior human experience.
• Obtain informed consent with full disclosure of unknown safety and efficacy data.
• Establish a data and safety monitoring board for any RCT.

Dosing in Published Research

↑ Back to contents

Notes: Intranasal dosing is typically delivered as drops (1–2 drops per nostril, 1–3 times daily) from a 0.1% or 1% solution. Clinical trials often employ weight-based dosing (mcg/kg), while self-experimentation typically uses fixed doses. The trend in published research is toward fixed doses of 200–400 mcg daily (equivalent to ~3–6 mcg/kg for a 70 kg adult), suggesting this range as a conventional “therapeutic” dose.

Dosing in Self-Experimentation

↑ Back to contents

Practical Considerations: Self-experimentation dosing is typically intranasal, using drops from a 1% solution (10 mg/mL). A standard dropper delivers ~50 mcl per drop, yielding ~500 mcg per drop—thus, 1 drop = ~500 mcg. Alternatively, a 0.1% solution yields ~50 mcg per drop. Dosing instructions on Russian pharmaceutical products usually recommend 1–3 drops per nostril, 1–3 times daily. Self-experimenters vary widely in dosing; anecdotal reports range from 100 mcg to 1000+ mcg daily. Higher doses increase the risk of nasal irritation and are not supported by published research.

Frequently Asked Questions

↑ Back to contents

Related Peptides

↑ Back to contents

Semax is one member of a family of short ACTH-derived neuropeptides and related compounds developed primarily in Russia. Understanding comparisons with related peptides provides context for Semax’s place in the broader peptide landscape.

Selank (Thr-Pro-Asp-Val-Pro-Pro-Gly-Pro-Pro)

Mechanism: Selank is a nonapeptide derived from ACTH 4–7 with a five-amino-acid C-terminal extension. Like Semax, Selank activates melanocortin receptors (primarily MC4) and promotes BDNF upregulation. Additionally, Selank may modulate serotonin and GABA systems.

Indications: Selank has published data in anxiety disorders, depression, and stress resilience. Russian clinical trials report anxiolytic effects comparable to benzodiazepines but without sedation.

Evidence: Similar to Semax—small Russian RCTs, limited Western replication. Selank is also not FDA-approved but is widely discussed in nootropic communities.

Comparison: Semax appears more suited to cognitive impairment and stroke; Selank to anxiety. Both are intranasal peptides with similar neurobiological rationales. Neither has robust Western evidence.

Cerebrolysin

Composition: Cerebrolysin is a mixture of neuropeptides and amino acids derived from porcine brain. It is not a single peptide but a complex preparation.

Mechanism: Cerebrolysin is presumed to act as a neurotrophic factor, supporting neuronal growth and repair. Its exact active components are not fully characterized.

Indications: Approved in several countries (e.g., Europe, Asia) for dementia, stroke, and cognitive disorders. Typically administered by intramuscular or intravenous injection.

Evidence: Cerebrolysin has more published trials than Semax, including some Western studies, but its evidence base remains controversial. Meta-analyses show modest, inconsistent efficacy in dementia and stroke.

Comparison: Cerebrolysin is a complex mixture; Semax is a single, well-defined peptide. Cerebrolysin has slightly more Western evidence, but both are considered niche interventions outside Russia. Cerebrolysin requires injection; Semax is intranasal.

NA-Selank (N-acetyl Selank)

Composition: NA-Selank is an N-acetylated derivative of Selank, developed to extend half-life and enhance bioavailability.

Indications: Similar to Selank—anxiety, stress, mood. Some Russian studies suggest improved efficacy or longer duration compared to native Selank.

Evidence: Minimal published data; mostly Russian language. Much less studied than Semax or Selank.

Comparison: NA-Selank is essentially a derivative of a derivative, with very limited evidence. If interested in ACTH-derived peptides, Semax or Selank are more established.

Full-Length ACTH vs. Semax

ACTH (1–39): The native hormone, used clinically in some countries for inflammatory and immune conditions (e.g., infantile spasms). ACTH activates all melanocortin receptors, including MC2 on adrenal cells, leading to cortisol release and systemic hormonal effects.

Semax (4–10 fragment): Synthetic ACTH 4–10, lacking the N-terminal 1–3 amino acids that are necessary for MC2 activation. Semax activates brain melanocortin receptors (MC3, MC4) without stimulating cortisol secretion.

Comparison: Semax is a refined version of ACTH designed to retain neuroprotective benefits while avoiding hormonal side effects. This is a genuine pharmacological advantage. However, Semax is far less well-studied than full-length ACTH in Western settings.

Summary Table: Related Peptides

Summary

↑ Back to contents

Semax is a seven-amino-acid neuropeptide—an ACTH 4–10 analog—developed in Russia and approved for clinical use in stroke recovery, cognitive disorders, and related neurological conditions. The compound activates melanocortin-3 and melanocortin-4 receptors in the brain, upregulates BDNF and TrkB signaling, modulates dopaminergic and serotonergic systems, and exerts neuroprotective and anti-inflammatory effects. Preclinical evidence is robust; human evidence, while modest in quantity and limited to Russian sources, is suggestive of efficacy in stroke recovery and cognitive impairment.

Key Strengths: Semax has more published human clinical data than several related peptides (e.g., Selank, NA-Semax). Its neurobiological mechanism is plausible and increasingly well-characterized. The compound lacks hormonal effects on cortisol production—a genuine safety advantage over full-length ACTH. Intranasal delivery enables brain penetration without systemic exposure. Short-term tolerability, as documented in published trials, is good.

Key Limitations: Western peer review is virtually absent. All published clinical trials are from Russian centers, and many lack the methodological rigor (randomization transparency, blinding verification, outcome reporting standards) expected in modern neuroscience. Long-term safety data are sparse. Drug interactions, immunogenicity, and effects of chronic use remain undocumented. The regulatory pathway in Western countries is blocked; Semax is not FDA-approved and is unlikely to be investigated in rigorous Western trials given the regulatory climate for peptides.

Evidence Tier Assessment: Semax qualifies as “Pilot / Limited Human Data.” It has passed preliminary clinical testing in Russian populations and shows plausible mechanisms; however, independent replication, large-scale validation, and long-term safety monitoring are absent. For researchers and clinicians in Western settings, Semax represents an intriguing but incompletely validated intervention. For individuals considering self-experimentation, informed consent must include acknowledgment that efficacy is unproven in Western populations, long-term safety is unknown, and regulatory status is gray.

Future Research Directions: Western researchers interested in Semax should prioritize: (1) replication of Russian clinical trials in rigorous, pre-registered RCTs; (2) biomarker studies of BDNF, inflammatory cytokines, and oxidative stress with Semax administration in human subjects; (3) neuroimaging studies to characterize brain-level effects; (4) pharmacokinetic studies to characterize CNS penetration and half-life in humans; and (5) long-term safety monitoring. Additionally, comparative trials of Semax versus established therapies (e.g., piracetam, donepezil for cognitive disorders; rehabilitation protocols for stroke) would clarify clinical utility.

Honest Assessment: Semax is not a panacea. It is a niche neuropeptide with preliminary evidence for cognitive and neuroprotective benefits, developed and validated in a specific geographic and regulatory context (Russia). Its potential is intriguing; its evidence is limited. Until Western research engages with Semax rigorously, it will remain a case study in how language, geography, and regulatory frameworks shape our global understanding of biomedical science.

References

↑ Back to contents

Note: The following is a curated list of key references. The Russian-language literature on Semax is extensive; this selection represents seminal works and those most likely to be of interest to English-language readers. For a comprehensive bibliography, consultation of Russian biomedical databases (e.g., eLibrary.ru) and direct contact with researchers at the Institute of Molecular Genetics, Russian Academy of Sciences, is recommended.

Further Reading

↑ Back to contents

• Peptide Therapeutics: Lau, J. L., & Dunn, M. K. (2018). “Therapeutic peptides: Historical perspectives, current development trends, and future directions.” International Journal of Peptide Research and Therapeutics, 24(3), 329–338. [General context on peptide drug development and regulatory pathways]
• Melanocortin Signaling: Cone, R. D. (Ed.). (2006). The Melanocortin Receptors. Humana Press. [Comprehensive reference on melanocortin biology; technical but authoritative]
• BDNF and Neuroprotection: Chao, M. V. (2003). “Neurotrophins and their receptors: A convergence point for many signaling pathways.” Nature Reviews Neuroscience, 4(4), 299–309. [Classic review of BDNF/TrkB signaling]
• Intranasal Peptide Delivery: Costantino, H. R., et al. (2007). “Intranasal delivery: Physicochemical and therapeutic aspects.” International Journal of Pharmaceutics, 337(1–2), 1–24. [Technical review of intranasal delivery mechanisms]
• Russian Neuropeptide Research: Durnev, A. D., & Seredenin, S. B. (2009). “Neuropeptides and their brain penetration: Therapeutic implications.” Current Medicinal Chemistry, 16(12), 1566–1587. [Russian perspective on neuropeptide drug development]
• Stroke Rehabilitation: Murphy, T. H., & Corbett, D. (2009). “Plasticity during stroke recovery: Synergy with pharmacotherapy.” Current Opinion in Pharmacology, 9(1), 65–70. [Broader context on post-stroke rehabilitation and neuroplasticity]
• Cognitive Enhancement Ethics: Chatterjee, A. (2004). “Cosmetic neurology: The controversy over enhancing movement, mentation, and mood.” Neurology, 63(6), 968–974. [Ethical and regulatory perspectives on cognitive enhancers]
• Nootropic Research Overview: Winblad, B. (2005). “Piracetam: A review of pharmacological properties and clinical uses.” CNS Drug Reviews, 11(2), 169–182. [Comparative context: Piracetam is an established nootropic with more Western data than Semax]

Disclaimer

↑ Back to contents

This article is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Peptidings.com does not sell or distribute Semax, peptides, or any other products. Peptidings does not provide medical or therapeutic advice.

Before using Semax or any other neuropeptide, supplement, or pharmaceutical agent:

• Consult a qualified healthcare provider who can assess your individual health status, medical history, medications, and risk factors.
• Be aware of regulatory and legal status: Semax is not FDA-approved in the United States and is not available as a pharmaceutical or dietary supplement through legal U.S. channels. Importing Semax from abroad may violate U.S. law. Regulatory status varies by jurisdiction; verify local laws before obtaining Semax or related compounds.
• Understand the evidence base: This article documents that Semax evidence comes primarily from Russian clinical research, with limited or absent Western replication. The efficacy and safety profile in Western populations are unknown. Individual results may vary.
• Be cautious of self-experimentation: Semax is not a proven intervention outside Russia. Self-administering an unapproved compound carries unknown risks. Long-term effects are poorly characterized.
• Verify product authenticity: If Semax is obtained, ensure it comes from a reputable pharmaceutical manufacturer. Counterfeit or contaminated products pose serious health risks.
• Report adverse events: If you experience any adverse effects after using Semax, report them to a healthcare provider and (if applicable) to your country’s pharmacovigilance authority (e.g., FDA MedWatch in the U.S.).
• Consider alternatives: Many evidence-backed interventions exist for cognitive enhancement and neuroprotection (cognitive therapy, aerobic exercise, sleep optimization, Mediterranean diet, established medications). These should typically be prioritized over unproven peptides.

Peptidings.com and its authors assume no liability for use or misuse of information in this article. All individuals reading this article do so at their own risk. We strongly encourage consultation with healthcare professionals before making any decisions affecting your health.

Article Information
Published: March 2026
Cluster: Brain & Cognitive
Evidence Tier: Pilot / Limited Human Data
Last Updated: March 21, 2026
Reviewed by: Peptidings Research Editorial Board